Investment
Features
FeesSafety
Academy
More
Pluang+

CLPS regains Nasdaq compliance after its stock price stays above $1 for 10 days

Market News
04 Sep 2026
PRNewsWire
View Source
Bullish
CLPS regains Nasdaq compliance after its stock price stays above $1 for 10 days

CLPS Incorporation announced it has regained compliance with Nasdaq's minimum bid price rule after its stock price remained at or above $1.00 per share for 10 consecutive trading days from August 20 to September 2, 2026. This means CLPS is now fully compliant with Nasdaq Listing Rule 5450(a)(1), closing the previous issue. The company operates globally in AI, cloud computing, fintech, and other sectors, positioning itself for continued growth. Investors can view more details on the company's website or social media channels.

More News

UNFI Q4 revenue dips 1.6% but EPS rebounds to $0.61-$0.62, signaling strong profit recovery

UNFI Q4 revenue dips 1.6% but EPS rebounds to $0.61-$0.62, signaling strong profit recovery

United Natural Foods (UNFI) is set to report Q4 earnings with revenue expected around $7.71 billion, a slight 1.6% decline from last year due to network optimization. Despite the revenue drop, EPS is forecasted to rise sharply to $0.61-$0.62, a signi...

Company Fundamentals
Bullish
57 minutes ago
Oracle's strong financials and AI investments boost analyst price target by 36%.

Oracle's strong financials and AI investments boost analyst price target by 36%.

Oracle reported strong fiscal 2026 results with 17% revenue growth to $67 billion and a 36% net income increase, driven by a 75% surge in its cloud infrastructure segment. Despite a recent 55% stock price drop from its peak, Morgan Stanley raised Ora...

Analyst Insights
Bullish
1 hour ago
RBC Capital raises Zscaler price target to $210 on strong revenue growth and AI-driven innovation.

RBC Capital raises Zscaler price target to $210 on strong revenue growth and AI-driven innovation.

RBC Capital increased its price target for cybersecurity firm Zscaler to $210, maintaining an "Outperform" rating due to the company's strong financial results and AI innovation. Zscaler reported a 25% rise in revenue and Annual Recurring Revenue, su...

Analyst Insights
Bullish
1 hour ago
Lululemon shares drop 18% as company cuts full-year forecast amid sales decline.

Lululemon shares drop 18% as company cuts full-year forecast amid sales decline.

Lululemon Athletica's shares fell about 18% after the company lowered its full-year financial forecast for the second time, reflecting ongoing challenges. In Q2 2026, total net revenue dropped 4% to $2.40 billion, with a 10% fall in comparable sales ...

Company Fundamentals
Bearish
2 hours ago
Teva gains bullish momentum after positive celiac disease trial and UBS upgrades price target to $48

Teva gains bullish momentum after positive celiac disease trial and UBS upgrades price target to $48

Teva Pharmaceutical Industries received a boost as UBS reaffirmed its "Buy" rating and raised the price target to $48, up from $36.62. This follows positive Phase 2a clinical trial results for TEV '408, a drug showing significant prevention of intest...

Analyst Insights
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App